Hartono Alifiani Bonita, Kang Hong-Jun, Shi Lawrence, Phipps Whitney, Ungerleider Nathan, Giardina Alexandra, Chen WeiPing, Spraggon Lee, Somwar Romel, Moroz Krzysztof, Drewry David H, Burow Matthew E, Flemington Erik, Ladanyi Marc, Lee Sean Bong
Tulane University School of Medicine, Department of Pathology and Laboratory Medicine, New Orleans, LA, USA.
Genomics Core, National Institute of Diabetes and Digestive and Kidney Diseases, Maryland, USA.
Oncogenesis. 2022 Apr 20;11(1):18. doi: 10.1038/s41389-022-00395-6.
Desmoplastic Small Round Cell Tumor (DSRCT) is a rare and aggressive malignant cancer caused by a chromosomal translocation t(11;22)(p13;q12) that produces an oncogenic transcription factor, EWSR1-WT1. EWSR1-WT1 is essential for the initiation and progression of DSRCT. However, the precise mechanism by which EWSR1-WT1 drives DSRCT oncogenesis remains unresolved. Through our integrative gene expression analysis, we identified Salt Inducible Kinase 1 (SIK1) as a direct target of EWSR1-WT1. SIK1 as a member of the AMPK related kinase is involved in many biological processes. We showed that depletion of SIK1 causes inhibition of tumor cell growth, similar to the growth inhibition observed when EWSR1-WT1 is depleted. We further showed that silencing SIK1 leads to cessation of DNA replication in DSRCT cells and inhibition of tumor growth in vivo. Lastly, combined inhibition of SIK1 and CHEK1with small molecule inhibitors, YKL-05-099 and prexasertib, respectively, showed enhanced cytotoxicity in DSRCT cells compared to inhibition of either kinases alone. This work identified SIK1 as a new potential therapeutic target in DSRCT and the efficacy of SIK1 inhibition may be improved when combined with other intervention strategies.
促纤维增生性小圆细胞肿瘤(DSRCT)是一种罕见且侵袭性强的恶性肿瘤,由染色体易位t(11;22)(p13;q12)引起,该易位产生一种致癌转录因子EWSR1-WT1。EWSR1-WT1对DSRCT的发生和发展至关重要。然而,EWSR1-WT1驱动DSRCT肿瘤发生的确切机制仍未明确。通过我们的综合基因表达分析,我们确定盐诱导激酶1(SIK1)是EWSR1-WT1的直接靶点。SIK1作为AMPK相关激酶的成员,参与许多生物学过程。我们发现,敲低SIK1会导致肿瘤细胞生长受到抑制,这与敲低EWSR1-WT1时观察到的生长抑制相似。我们进一步表明,沉默SIK1会导致DSRCT细胞中的DNA复制停止,并在体内抑制肿瘤生长。最后,分别用小分子抑制剂YKL-05-099和prexasertib联合抑制SIK1和CHEK1,与单独抑制任何一种激酶相比,在DSRCT细胞中显示出增强的细胞毒性。这项工作确定SIK1是DSRCT中一个新的潜在治疗靶点,并且当与其他干预策略联合使用时,抑制SIK1的疗效可能会提高。